Get startedLog in
    Picture of Lytix Biopharma AS logo

    LYTIX — Lytix Biopharma AS News Story

    0.000.00%
    no flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapMomentum Trap
    All News

    05 Study Presented At Esmo 2023

    Picture of Lytix Biopharma AS logoLytix Biopharma AS
    23/10/2023 07:08
    Oct 23 (Reuters) - Lytix Biopharma AS  LYTIX.OL :
    * ENCOURAGING PRELIMINARY DATA FROM LYTIX BIOPHARMA'S
ATLAS-IT-05
STUDY PRESENTED AT ESMO 2023
    * COMBINATION WITH LTX-315 AND PEMBROLIZUMAB DEMONSTRATES
PROLONGED STABILIZATION IN PATIENT POPULATION WITH A DISEASE
CONTROL RATE OF 43%

Source text for Eikon:  ID:nObiH3C24a 
Further company coverage:  LYTIX.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))

    Recent news on Lytix Biopharma AS

    See all news